Protide Pharmaceuticals offers the discovery, development and commercialization of technologies and processes that are used in transfusion medicines, as well as clinical therapies and cell engineering and transplantations. In operation for more than 20 years, the company offers services in over 30 countries. Its clients include patients, scientists and physicians. The company provides products under the Stemsol, TM-235, TCH, pZerve and Cellvation brands. It sells through a network of distributors. Protide Pharmaceuticals operates the Celox Laboratories division, which offers products for measuring and interpreting the dimensions of biology and medicines.